glp-1 for obesity monroe Weight Loss Specialist in Langhorne and Philadelphia, PA 3 Takeaways from the Landmark

Given the large number of people who might benefit from these medications for weight loss, they could have a meaningful and long-term impact on the costs of health benefits

Some trials in overweight individuals with type 1 diabetes report up to a 13.3 percent reduction in body weight when taking the SGLT-2 inhibitor empagliflozin

Survodutide is a dual GLP-1/glucagon receptor agonist

This raises theoretical concerns about oral contraceptive absorption

For example, in the LEADER trial, when compared with placebo, liraglutide decreased the incidence of major cardiovascular events (MACE) by 13%, cardiovascular death by 22% and all-cause death by 15% among T2DM patients with CVD, on a standard treatment basis [4]

That does not mean you have failed